Mechanism studies have shown that iguratimod not only inhibits the function of CD4+ T cells in RA patients, but also inhibits the function of CD4+ T cells in RA patients by regulating glucose metabolism, and inhibits the function of CD4+ T cells in RA patients by regulating the Hif1α-HK2 axis (36). This evidence concerns the gene HIF1A and rheumatoid arthritis.